Table 1.
Details of cattle at five sites used in a trial of the efficacy of gamithromycin in preventing clinical bovine respiratory disease
| Number enrolled and treated | Number included in efficacy analysis | ||||||
|---|---|---|---|---|---|---|---|
| Trial site | G* | Control† | Breeds | Age (months) | Weight (kg) | G | Control |
| France | 43 | 44 | CH, CC, L, BA, CB | 7-23 | 152-582 | 42 | 43 |
| Germany 1 | 60 | 60 | FV | <1-2 | 73-139 | 60 | 60 |
| Germany 2 | 63 | 63 | FV | <1-3 | 54-88 | 61 | 63 |
| Italy 1 | 121 | 121 | CH, CC | 7-18 | 198-390 | 121 | 121 |
| Italy 2 | 113 | 114 | S, A, L, CH, CC | 4-18 | 200-430 | 113 | 114 |
| Total | 400 | 402 | <1-23 | 54-582 | 397 | 401 | |
*
Treated with a single dose of 150 mg/ml gamithromycin injectable solution at 6 mg/kg (2 ml/50 kg) bodyweight
†
Treated with a single injection of sterile 0.9 per cent saline solution at 2 ml/50 kg bodyweight
A Aubrac, BA Blonde d'Aquitaine, CB Crossbred, CC Charolais cross, CH Charolais, FV Fleckvieh (German Simmental), L Limousin, S Saler